CAMPATH-IH in multiple sclerosis - PubMed (original) (raw)
doi: 10.1177/135245859600100616.
A Coles, M Wing, J Thorpe, D Miller, I Moseley, J Issacs, G Hale, D Clayton, N Scolding, H Waldmann, A Compston
Affiliations
- PMID: 9345418
- DOI: 10.1177/135245859600100616
CAMPATH-IH in multiple sclerosis
T Moreau et al. Mult Scler. 1996 Jul.
Abstract
In a pilot study, seven patients with multiple sclerosis were treated with CAMPATH-IH which targets the CD52 antigen present on lymphocytes and monocytes. There was a substantial reduction in disease activity as measured by gadoliunium-enhancing lesions on MRI. Encouraged by this result a further seven patients have been treated with CAMPATH-IH; four also received anti-CD4 antibody. Lymphopaenia developed rapidly and was sustained for at least one year. In 12 patients, the first infusion of antibody was characterised by significant exacerbation or re-awakening of pre-existing symptoms lasting several hours. These clinical effects of antibody treatment correlated with increased levels of circulating cytokines. Peak levels of tumour necrosis factor alpha (TNF alpha) and interferon gamma (IFN gamma) occurred at 2 h whereas the rise in interleukin-6 (IL-6) was significantly delayed and peaked at 4 h after starting antibody treatment. The neurological symptoms could not be attributed directly to pyrexia and were not provoked (in one patient) by an artificial rise in temperature. In the remaining two patients, a single pre-treatment with intravenous methylprednisolone (500 mg) prevented both the transient increase in neurological symptoms and the cytokine release. Our results suggest that soluble immune mediators contribute to symptom production in multiple sclerosis by directly or indirectly blocking conduction through partially demyelinated pathways.
Similar articles
- Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.
Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, Compston A. Moreau T, et al. Brain. 1996 Feb;119 ( Pt 1):225-37. doi: 10.1093/brain/119.1.225. Brain. 1996. PMID: 8624684 - Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.
Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, Miller D, Waldmann H, Compston A. Coles AJ, et al. Ann Neurol. 1999 Sep;46(3):296-304. doi: 10.1002/1531-8249(199909)46:3<296::aid-ana4>3.0.co;2-#. Ann Neurol. 1999. PMID: 10482259 Clinical Trial. - Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.
Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Compston DA, Coles AJ. Cox AL, et al. Eur J Immunol. 2005 Nov;35(11):3332-42. doi: 10.1002/eji.200535075. Eur J Immunol. 2005. PMID: 16231285 Clinical Trial. - Campath-1H treatment of multiple sclerosis.
Jones JL, Coles AJ. Jones JL, et al. Neurodegener Dis. 2008;5(1):27-31. doi: 10.1159/000109935. Neurodegener Dis. 2008. PMID: 18075272 Review. - Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients.
Knechtle SJ. Knechtle SJ. Pediatr Transplant. 2004 Apr;8(2):106-12. doi: 10.1046/j.1399-3046.2003.00139.x. Pediatr Transplant. 2004. PMID: 15049789 Review.
Cited by
- Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients.
Akgün K, Behrens J, Schriefer D, Ziemssen T. Akgün K, et al. Int J Mol Sci. 2022 Nov 9;23(22):13759. doi: 10.3390/ijms232213759. Int J Mol Sci. 2022. PMID: 36430240 Free PMC article. - Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era.
Kasarello K, Mirowska-Guzel D. Kasarello K, et al. Immunotargets Ther. 2021 Jul 7;10:237-246. doi: 10.2147/ITT.S240890. eCollection 2021. Immunotargets Ther. 2021. PMID: 34268256 Free PMC article. Review. - Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children.
Fragoso YD, Adoni T, Brooks JBB, Finkelsztejn A, da Gama PD, Grzesiuk AK, Marques VD, Parolin MFK, Sato HK, Varela DL, Vasconcelos CCF. Fragoso YD, et al. Neurol Ther. 2018 Dec;7(2):207-232. doi: 10.1007/s40120-018-0110-3. Epub 2018 Aug 30. Neurol Ther. 2018. PMID: 30167914 Free PMC article. Review. - Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS.
Thomas K, Eisele J, Rodriguez-Leal FA, Hainke U, Ziemssen T. Thomas K, et al. Neurol Neuroimmunol Neuroinflamm. 2016 Apr 29;3(3):e228. doi: 10.1212/NXI.0000000000000228. eCollection 2016 Jun. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 27213173 Free PMC article. - Dendritic cells as therapeutic targets in neuroinflammation.
Luessi F, Zipp F, Witsch E. Luessi F, et al. Cell Mol Life Sci. 2016 Jul;73(13):2425-50. doi: 10.1007/s00018-016-2170-9. Epub 2016 Mar 12. Cell Mol Life Sci. 2016. PMID: 26970979 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials